Elevated sCD163 levels have been associated with poor survival in patients with different types of cancer, including multiple myeloma [20], gastric cancer [21], colorectal cancer [22], melanoma [23], hepatocellular carcinoma [24,25], epithelial ovarian cancer [26], classical Hodgkin’s lymphoma [27], B-cell lymphocytic leukemia [28] and diffuse large B-cell lymphoma [29] but not in patients with renal cell carcinoma [30] (Supplementary Table S2). Here, CD163 is linked to hepatocellular carcinoma.